Skip to main content

Haroon Ahmad, MD

Academic Title:

Assistant Professor

Primary Appointment:


Secondary Appointment(s):


Additional Title:

Associate Member Greenbaum Cancer Center

Phone (Primary):




Education and Training

University of Maryland, Baltimore County, BS Biochemistry and Molecular Biology, 2007

University of Virginia, School of Medicine, MD, 2012

United States FDA, Dept of Epidemiology ORISE Fellow, 2013

East Carolina University, Internal Medicine Internship, 2014

Rutgers-Robert Wood Johnson, Neurology Residency, 2017

University of Virginia, Neuro-Oncology Fellowship, 2019


Dr. Ahmad is an Assistant Professor at the University of Maryland School of Medicine and a specialist in the diagnosis and treatment of central nervous system tumors. His work and research are focused on cancer of the brain, spinal cord, and other cancers which have spread to the brain. He is also a board certified neurologist and is trained in the treatment of neurologic conditions such as stroke, epilepsy, headache, etc.

At UMMC he plays an integral part in the multi-disciplinary team treating brain tumors. Along with neurosurgery, radiation oncology, pathology, and radiology, he provides expert opinion on all brain tumor cases at the weekly UMMC neuro-oncology tumor board. This tumor board is designed to provide patients of UMMC world-class care in the management of their cancer. This group also develops and enrolls patients in cutting edge clinical trials.

As a native of Baltimore and a graduate of the University of Maryland system, he takes particular pride in the health system and the treatment of patients from the state of Maryland. 

Research/Clinical Keywords

Glioblastoma, Glioma, Immunotherapy, meningioma, checkpoint inhibitor, Car-T, Oligodendroglioma, Astrocytoma, CNS Lymphoma, Metastases, Pilocytic astrocytoma, pleomorphic xanthrocytoma, High Grade Glioma, Low Grade Glioma, Radiation Therapy, Proton

Highlighted Publications

1. Checkpoint Inhibitor Failure in Hypermutated and Mismatch Repair-Mutated Recurrent High-Grade Gliomas. Ahmad H, Fadul CE, Schiff D, Purow B. Neuro-Oncology Practice 2019 April 07


2. Oligodendroglioma Confers Higher Risk of Radiation Necrosis, Ahmad H, Martin D, Patel SH, Donahue J, Lopes MB, Purow B, Schiff D, Fadul CE, J Neurooncol.2019 Nov;145(2):309-319. doi: 10.1007/s11060-019-03297-7. Epub 2019 Sep 23.


3. Multimodality Therapy of Patients with Refractory Meningiomas, Ahmad H, Schiff D. Curr Treat Options Oncol. 2019 May 9;20(6):50. PubMed PMID: 31073797.


4. Neurologic Side Effects of Checkpoint Inhibitor Therapy. Ahmad H, Jo J, Gaughan E, Fadul CE. SITC Handbook, SITC’s Guide to Managing Immunotherapy Toxicity. Edited by Ernstoff M, Puzanov I, Robert C, Diab A, Hersey P, New York, Springer Publishing Company. 2018


5. Safety of Endovascular Intervention for Acute Stroke in Patients on Anticoagulation Kurowski D, Jonczak K, Shah Q, Yaghi S, Marshall RS, Ahmad H, McKinney J, Torres J, Ishida K, Cucchiara J Stroke Cerebrovasc Dis. 2017 May;26(5):11041109. PubMed PMID: 28110890